References
- Wang J, Seebacher N, Shi H, Kan Q, and Duan Z: Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8, 84559–84571, 2017.
- Yusuf R, Duan Z, Lamendola D, Penson R, and Seiden M: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3, 1–19, 2003.
- Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219, 2006.
- Xu X, Zhang Y, Li W, Miao H, Zhang H, et al.: Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol 92, 220–234, 2014.
- Duan W, Paka L, and Pillarisetti S: Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovasc Diabetol 4, 16, 2005.
- Anderson J, Nicolosi R, and Borzelleca J: Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 43, 187–201, 2005.
- Zahedipour F, Dalirfardouei R, Karimi G, and Jamialahmadi K: Molecular mechanisms of anticancer effects of Glucosamine. Biomed Pharmacother 95, 1051–1058, 2017.
- Zachara NE and Hart GW: The emerging significance of O-GlcNAc in cellular regulation. Chem Rev 102, 431–438, 2002.
- Jamialahmadi K, Arasteh O, Riahi MM, Mehri S, Riahi-Zanjani B, et al.: Protective effects of glucosamine hydrochloride against free radical-induced erythrocytes damage. Environ Toxicol Pharmacol 38, 212–219, 2014.
- Jamialahmadi K, Soltani F, Nabavi Fard M, Behravan J, and Mosaffa F: Assessment of protective effects of glucosamine and N-acetyl glucosamine against DNA damage induced by hydrogen peroxide in human lymphocytes. Drug Chem Toxicol 37, 427–432, 2014.
- Dalirfardouei R, Karimi G, and Jamialahmadi K: Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. Life Sci 152, 21–29, 2016.
- Quastel J and Cantero A: Inhibition of tumour growth by D-glucosamine. Nature 171, 252, 1953.
- Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, et al.: O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115, 715–725, 2003.
- Liu B-Q, Meng X, Li C, Gao Y-Y, Li N, et al.: Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol Med 43, 487, 2011.
- Oh H-J, Lee JS, Song D-K, Shin D-H, Jang B-C, et al.: D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun 360, 840–845, 2007.
- Kim D-S, Park S-S, Nam B-H, Kim I-H, and Kim S-Y: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66, 10936–10943, 2006.
- Kim D-S, Park K-S, Jeong K-C, Lee BI, Lee C-H, et al.: Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 273, 243–249, 2009.
- Nourbakhsh M, Jaafari MR, Lage H, Abnous K, Mosaffa F, et al.: Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 18, 385, 2015.
- Salazar J, Bello L, Chávez M, Añez R, Rojas J, et al.: Glucosamine for osteoarthritis: biological effects, clinical efficacy, and safety on glucose metabolism. Arthritis 2014, 1, 2014.
- Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, et al.: Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21, 1503–1512, 2010.
- Chesnokov V, Sun C, and Itakura K: Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling. Cancer Cell Int 9, 25, 2009.
- Jeong K-C, Ahn K-O, Lee BI, Lee C-H, and Kim S-Y: The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition. J Cancer Res Clin Oncol 136, 143–150, 2010.
- Lee J, Kim Y-S, Choi D-H, Bang MS, Han TR, et al.: Transglutaminase 2 induces NF-κB activation via a novel pathway in BV-2 microglia. J Biol Chem, 17, 53725–53735, 2004.
- Setnikar I and Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 51, 699–725, 2001.